SCHEMBL17520326

SCHEMBL17520326

COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCCN1CCCCC1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 16/20 0.85
KDR P35968 16/20 0.85
FGFR1 P11362 12/20 0.85
FLT1 P17948 12/20 0.85
FLT4 P35916 11/20 0.85
RET P07949 3/20 0.70
KIF5B P33176 3/20 0.70
PDGFRB P09619 3/20 0.68
FGFR2 P21802 2/20 0.68
FGFR4 P22455 2/20 0.68
FGFR3 P22607 2/20 0.68
TEK Q02763 2/20 0.68
BMPR1B O00238 1/20 0.68
PLK4 O00444 1/20 0.68
CIT O14578 1/20 0.68
GAK O14976 1/20 0.68
EPHB6 O15197 1/20 0.68
RIPK2 O43353 1/20 0.68
ROCK2 O75116 1/20 0.68
STK10 O94804 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17520359 0.99 KDR (0.87) EGFRKDRFGFR1FLT1FLT4
SCHEMBL17520350 0.96 KDR (0.82) EGFRKDRFGFR1FLT1FLT4
SCHEMBL17520347 0.95 KDR (0.82) EGFRKDRFGFR1FLT1FLT4
Hydrochloric Acid SCHEMBL27218174 0.92 EGFR (1.00) EGFRKDRFGFR1FLT1FLT4
SCHEMBL7867160 0.91 KDR (0.83) EGFRKDRFGFR1FLT1FLT4
Hydrochloric Acid SCHEMBL7866060 0.91 KDR (0.84) EGFRKDRFGFR1FLT1FLT4
SCHEMBL19220790 0.90 EGFR (0.81) EGFRKDRFGFR1FLT1FLT4
SCHEMBL5458741 0.90 KDR (0.75) EGFRKDRFGFR1FLT1FLT4
SCHEMBL1467784 0.90 KDR (0.83) EGFRKDRFGFR1FLT1FLT4
SCHEMBL1468087 0.90 FGFR1 (0.98) EGFRKDRFGFR1FLT1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3181554-B1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) 2020-10-28 EP disclosed
US-10774079-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2020-09-15 US disclosed
US-10774079-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2020-09-15 US disclosed
US-10421754-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2019-09-24 US disclosed
US-10421754-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2019-09-24 US disclosed
US-20170226099-A1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-08-10 US disclosed
US-20170226099-A1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-08-10 US disclosed
US-20170226099-A1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-08-10 US disclosed
EP-3181554-A1 QUINAZOLINE DERIVATIVE CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2017-06-21 EP disclosed
WO-2016023330-A1 QUINAZOLINE DERIVATIVE 石药集团中奇制药技术(石家庄)有限公司 2016-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10774079-B2 Quinazoline derivative H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 EGFR 3701/4885KDR 3669/4885FGFR1 4724/4885
US-10421754-B2 Quinazoline derivative H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 EGFR 3701/4885KDR 3669/4885FGFR1 4724/4885
US-20170226099-A1 QUINAZOLINE DERIVATIVE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 EGFR 3701/4885KDR 3669/4885FGFR1 4724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.